OKYO PHARMA LTD SP.ADR/65 (OK10) - Total Liabilities
Based on the latest financial reports, OKYO PHARMA LTD SP.ADR/65 (OK10) has total liabilities worth €8.06 Million EUR (≈ $9.42 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See OK10 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
OKYO PHARMA LTD SP.ADR/65 - Total Liabilities Trend (2022–2025)
This chart illustrates how OKYO PHARMA LTD SP.ADR/65's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see OK10 total assets.
OKYO PHARMA LTD SP.ADR/65 Competitors by Total Liabilities
The table below lists competitors of OKYO PHARMA LTD SP.ADR/65 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Turism Hotelur
RO:EFO
|
Romania | RON36.76 Million |
|
DP Aircraft I Limited
LSE:DPA
|
UK | $95.47 Million |
|
CORESTATE Capital Holding S.A
F:CCAP
|
Germany | €725.00 Million |
|
UPA Corporation Bhd
KLSE:7757
|
Malaysia | RM29.74 Million |
|
Hung Chou Fiber Ind Co Ltd
TW:1413
|
Taiwan | NT$1.50 Billion |
|
Dancomech Holdings Bhd
KLSE:5276
|
Malaysia | RM43.77 Million |
|
Display Tech Co. Ltd
KQ:066670
|
Korea | ₩49.88 Billion |
|
Jin Yang Pharmaceutical Co. Ltd
KQ:007370
|
Korea | ₩111.51 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down OKYO PHARMA LTD SP.ADR/65's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of OKYO PHARMA LTD SP.ADR/65 to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OKYO PHARMA LTD SP.ADR/65's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OKYO PHARMA LTD SP.ADR/65 (2022–2025)
The table below shows the annual total liabilities of OKYO PHARMA LTD SP.ADR/65 from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | €9.23 Million ≈ $10.79 Million |
+24.34% |
| 2024-03-31 | €7.42 Million ≈ $8.68 Million |
+2.26% |
| 2023-03-31 | €7.26 Million ≈ $8.48 Million |
+436.30% |
| 2022-03-31 | €1.35 Million ≈ $1.58 Million |
-- |
About OKYO PHARMA LTD SP.ADR/65
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptid… Read more